August 18, 2020

Tracking the International Effort to Keep Clinical Trials for Non-COVID-19 Treatments Moving

Recently, public attention has been captured by the progress of medical treatments and vaccines against COVID-19, which are currently going through clinical trials (categorized into phases 1, 2 and 3).1

Regulatory agencies in the U.S. and other countries tasked with reviewing and approving these and other medical products have been issuing guidelines and Q&A documents to facilitate their expedited development.2

At the same time, medical products for conditions other than COVID-19 have faced significant headwinds with subject recruitment and retainment and the overall conduct of clinical trials.3

Scientists across government agencies, academia and industry are therefore exploring new ways to continue this much-needed work. Possible adjustments range from behavioral and physical modifications, for example, as recommended by the following regulatory agencies:

Further, as explained in the following publications, others have proposed new statistical solutions:

For additional information on these topics or for help with related regulatory issues, please contact Dr. Lana Lyapustina at Faegre Drinker.

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.